Reducing malaria transmission with engineered bacteria

利用工程细菌减少疟疾传播

基本信息

  • 批准号:
    8137946
  • 负责人:
  • 金额:
    $ 20.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-15 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The fight against the intolerable burden of malaria is restricted to the use of insecticides that kill the mosquito vector and drugs that kill the parasite in humans. Considering that recent estimates place the number humans infected with malaria at over 500 million (nearly 1 in 12 humans), the introduction of new means to counter the disease is urgently needed. We propose to develop a novel strategy to prevent the spread of malaria parasites by anopheline mosquitoes, based on genetic modification of bacteria that inhabit the gut of these insects. We will evaluate in detail the ability of two candidate bacterial species (Pantoea agglomerans and Asaia sp.) to colonize larval and adult mosquitoes and their ability to be transmitted vertically from one generation to the next. We will develop robust methods to secrete antimalarial effector proteins from each bacterial species to ensure that the effector proteins will reach the intended targets on the parasite or on the midgut epithelium. Different bacterial strains that secrete effector proteins will be evaluated for their efficacy to interfere with parasite development in the mosquito. Using the data obtained from engineered bacterial strains producing single effectors, we will create an optimal combination of strains that combine multiple effectors for maximum efficacy. Given that this funding mechanism is restricted in its time frame, no field trials are proposed although discussions with the relevant regulatory agency (US-EPA) are already underway. This research is expected to lead to the development of a novel weapon that can be used in combination with traditional control strategies (drugs, insecticides, vaccines) to combat malaria. PUBLIC HEALTH RELEVANCE: Malaria is one of the deadliest infectious diseases and kills an estimated 2 million persons every year. The mosquito is the obligatory vector for transmission. This project will devise new ways to interfere with the mosquito capacity to transmit the parasite, by genetically modifying bacteria that live in the mosquito midgut.
描述(申请人提供):与疟疾无法忍受的负担作斗争仅限于使用杀死蚊媒的杀虫剂和杀死人体寄生虫的药物。考虑到最近的估计数字显示感染疟疾的人数超过5亿(几乎每12人中就有1人感染),迫切需要引入新的手段来对抗这种疾病。我们建议开发一种新的策略,以防止疟疾寄生虫通过按蚊传播,这是基于对寄生在这些蚊子肠道中的细菌进行基因改造。我们将对两个候选细菌种(Pantoea agregans和Asaia sp.)的能力进行详细的评估。使幼虫和成年蚊子定居,并使它们能够从一代垂直传播到下一代。我们将开发强大的方法来分泌每个细菌物种的抗疟疾效应器蛋白,以确保效应器蛋白将到达寄生虫或中肠上皮上预定的目标。将评估分泌效应蛋白的不同细菌菌株干扰蚊子体内寄生虫发展的效果。使用从产生单一效应器的工程细菌菌株获得的数据,我们将创造出将多个效应器结合在一起以实现最大疗效的菌株的最佳组合。鉴于这一供资机制在时间范围内受到限制,尽管与相关监管机构(美国环保局)的讨论已经在进行中,但没有提议进行实地试验。这项研究有望开发出一种可与传统控制策略(药物、杀虫剂、疫苗)结合使用的新型武器,以抗击疟疾。 与公共卫生相关:疟疾是最致命的传染病之一,每年估计导致200万人死亡。蚊子是传播的必备媒介。该项目将设计新的方法来干扰蚊子传播寄生虫的能力,方法是对蚊子中肠内的细菌进行基因改造。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARCELO JACOBS-LORENA其他文献

MARCELO JACOBS-LORENA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARCELO JACOBS-LORENA', 18)}}的其他基金

Molecular mechanisms of Plasmodium fertilization
疟原虫受精的分子机制
  • 批准号:
    9212860
  • 财政年份:
    2016
  • 资助金额:
    $ 20.47万
  • 项目类别:
Molecular mechanisms of Plasmodium fertilization
疟原虫受精的分子机制
  • 批准号:
    10064068
  • 财政年份:
    2016
  • 资助金额:
    $ 20.47万
  • 项目类别:
Characterization of Plasmodium GAPDH as a candidate for development of a malaria pre-erythrocytic vaccine
疟原虫 GAPDH 作为开发疟疾前红细胞疫苗候选物的表征
  • 批准号:
    9228326
  • 财政年份:
    2016
  • 资助金额:
    $ 20.47万
  • 项目类别:
Brain vascular dysfunction in cerebral malaria
脑型疟疾的脑血管功能障碍
  • 批准号:
    9281895
  • 财政年份:
    2015
  • 资助金额:
    $ 20.47万
  • 项目类别:
Brain vascular dysfunction in cerebral malaria
脑型疟疾的脑血管功能障碍
  • 批准号:
    9529367
  • 财政年份:
    2015
  • 资助金额:
    $ 20.47万
  • 项目类别:
Brain vascular dysfunction in cerebral malaria
脑型疟疾的脑血管功能障碍
  • 批准号:
    9017256
  • 财政年份:
    2015
  • 资助金额:
    $ 20.47万
  • 项目类别:
2013 TROPICAL INFECTIOUS DISEASES: FROM BENCH TO FIELD GORDON RESEARCH CONFERENCE
2013 热带传染病:从实验室到现场戈登研究会议
  • 批准号:
    8452997
  • 财政年份:
    2013
  • 资助金额:
    $ 20.47万
  • 项目类别:
2011 Tropical Infectious Diseases Gordon Research Conference
2011年热带传染病戈登研究会议
  • 批准号:
    8119215
  • 财政年份:
    2011
  • 资助金额:
    $ 20.47万
  • 项目类别:
Reducing malaria transmission with engineered bacteria
利用工程细菌减少疟疾传播
  • 批准号:
    7869162
  • 财政年份:
    2010
  • 资助金额:
    $ 20.47万
  • 项目类别:
Vector biology-Using a mosquito pathogen as a delivery system for anti-malarial a
媒介生物学-使用蚊子病原体作为抗疟疾药物的传递系统
  • 批准号:
    7660719
  • 财政年份:
    2009
  • 资助金额:
    $ 20.47万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 20.47万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了